Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Getinge, Audiocast, Q3'26

By Inderes10/21/2026, 8:00 AM
Getinge

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Mattias Perjos
00:02 - 06:31

Thanks and welcome, everyone, to today's earnings call. As mentioned, I have our CFO, Agneta Palmér, with me today. And in the conference call today, we'll go through our performance and some highlights in the third quarter before opening up for the customary Q&A. So let's move to page number two right away, please. So we start looking at the development of some of our longer-term strategic KPIs. We continue to track clearly in line with our plan to increase the share of sales from recurring revenue. Accelerating the share of sales from high-margin products like, for example, our offerings in the BetteBags and Sterile Transfer, which have both had a very strong year so far. And all these activities are, of course, supported by solid and effective quality processes as well. So if we look at sales from recurring revenue, it continues to make up about two-thirds of our sales and the high-margin products are at 70% as of Q3. And when it comes to quality, the number of field actions in relation to sales has decreased significantly in the last three years. We are currently tracking slightly above last year's level, but remain within our expected range on this KPI. These improvements should, of course, be achieved also through responsible financial leverage and an attractive long-term return on invested capital. Let's move to page number three, please. So if we look at the key takeaways when it comes to the third quarter and with an emphasis on the financial KPIs overall, we delivered a healthy financial performance in the quarter with top-line growth. Net sales grew 2.1% organically with positive development in most of the business areas. Order intake increased by 2.6% organically. If we then look at the adjusted gross and EBITA margins. They were up in the quarter as a result of the continued positive underlying performance that we've seen for quite a while now. Margins were also supported by a remaining tariff refund of 45 million Swedish kronor. This led to another quarter with strong cash flow and a very solid financial position. Our financial leverage is at 1.5 right now, so well below the 2.5 times EBITDA internal threshold that we have. We have an internal threshold. So let's move to page number four and talk about some of the key events from the quarter. I think, first and foremost, I would like to share the information that we recently received regarding the results of our annual customer feedback survey. And I am very pleased to report that our Net Promoter Score has reached an all-time high. We also had very strong employee engagement, and these are two KPIs that are extremely important for long-term success. I'm also happy to say that we, at the end of the quarter, initiated the launch of the new version of our platform Cardiohelp II in CEE countries and in Hong Kong. And so far, this has been very well received by our customers. We look forward to continuing this launch, and within our digital health solutions, we launched Torin Plan Optimizer, which supports surgical planning in hospitals thanks to an AI-powered system. And just to quote the management at Klinikum Stuttgart in Germany, he mentioned that this supports better informed planning decisions and much more effective use of our existing surgical capacity. Furthermore, in collaboration with the Swedish non-profit organization, Lifted, we continued our support to the National Specialized Children’s Hospital Okhmatdyt in Kyiv through a donation of ECMO consumables. The hospital operates one of Ukraine's leading pediatric ECMO programs, treating critically ill children from across the country. And in 2025, the hospital reported that it doubled its ECMO capacity and this continues to trend in a good direction. We are very happy to be part of supporting this important initiative. It is really clear that our donation helps sustain life-saving capability. And then, just continuing on the pediatric track for a moment. We also received 510(k) clearance in the quarter for a new, smaller Edi catheter, which is used with our ventilators. And this makes it possible to support premature infants between 500 and 1,000 grams in weight. It is also very comforting to see that our sustainability KPIs are tracking well. Just to highlight two of them, compared to last year, we have reduced our scope 1 and 2 greenhouse gas emissions by more than 20%, and the share of renewable energy is above 70%. We can then move to page number five, please. So if we talk about our organic top-line growth, this was driven by Acute Care Therapies, Life Science, and Surgical Workflows in the quarter. So order intake grew 2.6% organically. The organic order intake in Acute Care Therapies increased primarily in ECLS therapy consumables and cardiac assist consumables. Life Sciences organic order intake declined slightly during the quarter. The positive performance in bioprocessing and service did not fully offset the continuing decline that we see within our washer-isolator and sterilizer subsegment. Surgical workflows increased, mainly driven by strong performance in operating room equipment such as surgical tables and lights. We then look at the net sales. We grew net sales by 2.1% in the quarter. This was mainly driven by disciplined work with pricing. With pricing, Acute Care Therapies increased net sales organically, primarily due to ECLS therapy consumables, intra-aortic balloon pumps and cardiac assist, and also our covered stents. Organic net sales for Life Science fell slightly following a continuing decline in washers, isolators, and sterilizers, and this was despite robust growth in sterile transfer in Surgical Workflows. Organic net sales rose slightly following growth in infection control and in our digital health solutions portfolio. We can then move to page number six, please. And I hand over to you for a moment.

Agneta Palmér
06:32 - 09:09

Thank you, Mattias. So, overall, we continue to improve our margins. And I am particularly pleased with that. The main driver of this is the underlying improvement in the business, mainly thanks to the disciplined pricing efforts that Mattias mentioned, but also positive mix shift and productivity. Let's have a look at adjusted gross profit. For the group, adjusted gross profit amounted to 4,343 million SEK in the quarter, primarily on the back of the factors I just mentioned, but also supported by the remaining tariff refund of approximately 45 million SEK. This led to an increase of the adjusted gross margin by 2.2 percentage points in total. Moving on to adjusted EBITDA, the effect from adjusted gross profit on the EBITDA margin was plus 1.7 percentage points. OPEX increased less than inflation, and adjusted for currency, OPEX had a slight positive impact on the margin of about 0.1 percentage points in the quarter, while FX impacted the margin by 0.3 percentage points. All in all, this resulted in an adjusted EBITDA of 1,278 million SEK and a margin of 15.1%. Let's move to page seven, please. So, the strong operating results further strengthen our financial position. Free cash flow was again above the 1 billion mark, amounting to 1,302 million SEK in the quarter compared with last year. Free cash flow was impacted by the improved operating profit and changes in working capital at the end of Q3. Net debt decreased to 10.4 billion SEK due to the cash flow generation. If we adjust for pension liabilities, net debt was at 8.1 billion SEK. This brings us to a leverage of 1.5 times adjusted EBITDA, which is well below the 2.5 which we have as an internal threshold. If we adjust for pension liabilities, leverage is at 1.1 times adjusted EBITDA. Cash amounted to approximately 3.2 billion SEK at the end of the quarter. So, all in all, we can conclude that the financial position continues to be strong. Let's then move to page eight, please. And back to you, Mattias.

Mattias Perjos
09:11 - 13:08

All right. Thank you, Agneta. Just one picture as well to show the traction that we are making towards our mid-term guidance span. So, looking at the rolling 12-month development for adjusted EBITDA margin, we have, over two years, improved from 12% to 15.6% normalized, which means excluding tariffs, we are at 15.8%. So even if excluding the tariff refund of 381 million SEK in Q2 and Q3 of 2026, we are at 14.5% compared to the capital markets update that we had in May 2024. We guided for an adjusted EBITDA margin span of 16% to 19% by the end of 2028. We have a bit more than two years until the end of 2028, and as you can see, we are steadily closing in on the span; the main drivers which will support us getting there, in spite of continued tariffs, are the gradual cost releases from the second half of this year, mainly impacting 2027 and 2028. And this is stemming from the regulatory submissions and the approval process when it comes to CardioSave and Cardiohelp II. We also have the mix shift to more recurring revenue and high-margin revenue that I mentioned in the beginning of the call. And we also rely on the continuous productivity measures and the key product launches that we've had recently and will have before 2028. With that, we can move over to page number nine, please. So if we then focus on the outlook for the remainder of 2026, as we all know, there are still some geopolitical uncertainties that we need to navigate. But based on the underlying demand that we see in our regular dialogue with customers, our expectation remains for organic net sales growth to be in the range of 3% to 5% for 2026, adjusted for the phase-out of Surgical Perfusion, and Surgical Perfusion is still expected to have net sales in 2026, declining from about 250 million to 50 million SEK. Year to date, we are at 2.5% organic growth and believe Q4 performance will take us into the span of 3 to 5%. Q4 is usually our largest quarter in terms of net sales, driven by multiple factors, especially on the customer side. Impactful deliveries can go out before year-end here. All involved are always making an incredible effort. We have seen this over the last 3 or 4 years, and we rely on that type of performance again for the end of this year. The uncertainty here is the main reason why we're not tightening the guidance span. We can then move to page 11, please. So just to talk about and summarize the key takeaways then. Overall, we have a solid financial performance with organic growth in the top line, and margins came in healthy in the quarter, primarily thanks to the improving underlying performance in our business and cash flow in the quarter. And it was very strong. Our financial position also remains very solid for 2026. We reiterate our guidance for organic net sales growth of 3 to 5%, adjusted for the phase out of Surgical Perfusion; our priorities for the last quarter of 2026 remain the same as they have been before. It is about addressing the remaining challenges when it comes to quality work and acute care therapies. It's about the sustainable productivity improvements and cost consciousness when navigating the political uncertainty that we see on a daily basis, and also addressing, of course, the impact from tariffs and, most importantly, continuing to create the added value for our customers, which you could really see when it comes to the Net Promoter score at an all-time high during this year. So with that said, I open up for questions.

Operator
13:10 - 13:28

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Filip Ekengren from Nordea. Please go ahead.

Filip Ekengren
13:30 - 13:48

Thank you, operator, and good morning. I have two questions. I will take them one by one. So starting with the outlook, that implies some growth acceleration in Q4. Obviously so. Which products or segments do you think will support that acceleration? And is the upper end still in place?

Mattias Perjos
13:50 - 14:33

Yeah. We don't disclose which categories we believe are most important when it comes to a specific quarter like this; I think the patterns that you've seen before will remain intact. So, Acute Care Therapies is definitely one of those categories, there are others as well. But other than that, we don't want to single out anything specific here. And I think it goes without saying that the lower part of the guidance span is easier and much more realistic than the upper part. But again, as I said, within the summary, we do have a lot of deliveries scheduled for the fourth quarter. And there are a lot of swing factors involved there. So that is the reason for not narrowing the span.

Filip Ekengren
14:35 - 14:49

That makes sense. Thank you. And then you highlighted some positive customer response following the launch of Cardiohelp II. Are our orders primarily replacing existing Cardiohelp systems? Or is it expanding your installed base?

Mattias Perjos
14:50 - 15:06

It is a mix of both. We don't disclose this, but it is a mix of both. This is a therapy that is in general expansion mode. So it is both about replacing but also opening up new centers and adding capacity in existing ones.

Filip Ekengren
15:09 - 15:10

Thank you so much. I will get back into the queue.

Mattias Perjos
15:11 - 15:11

Thank you.

Operator
15:16 - 15:20

The next question comes from Ludwig Germann from Handelsbanken. Please go ahead.

Ludwig Germann
15:22 - 15:43

Yes. Good morning. Thank you for taking my questions. I have the first one, which is a general question on demand. I am interested to hear what you are currently seeing and hearing from customers. So we see some peers reporting a more challenging demand situation. But you seem to be doing well. And I think you sound confident on the outlook here. But beyond the reported numbers, what are you seeing and hearing from your customers right now?

Mattias Perjos
15:45 - 16:38

I think that the general situation when it comes to demand is stable and positive. We see that across most categories. And this is a pattern that has been with us for a while. I think on the challenging side, it's mostly on the big capital part in life science that is still sluggish. I think one of the small bright spots in the quarter was that we had a little bit better momentum in the US for that category, which is the first in a while. But I describe the general situation as rather stable when it comes to both the surgical procedures that are being performed and the way they drive this demand in the short term. But I also think customers seem to have long-term faith in the future and are willing to also place capital. So, for example, order intake in surgical workflows for operating tables is one example of that.

Ludwig Germann
16:40 - 17:00

Okay. Thank you for that. And then a second question on order mix; you mentioned that the order intake was primarily increasing in ECLS therapy consumables, cardiac assist, and consumables in the total Act orders. Do you see any change in the mix when it comes to these consumables? Or would you say that they make up a normal share of total orders?

Mattias Perjos
17:04 - 17:13

Nothing to call out. I think from a mix pattern, what we've predicted and seen for a long while keeps happening and keeps unfolding, I would say.

Agneta Palmér
17:15 - 17:26

Okay. With that in mind, maybe just to add that Q4 is usually a bit of a different mix, more capital heavy as per seasonal pattern.

Ludwig Germann
17:28 - 17:42

Understood. Thank you for, for that. And just a quick one, if I may. I noticed that acquisition costs in the quarter were 33 million. I know it's a small number, but it still stands out a bit compared to previous quarters. Could you comment on what is driving this increase?

Mattias Perjos
17:43 - 18:09

Yeah. Nothing specific. Other than that, we remain very active when it comes to looking at M&A. So there is a good inflow in the funnel of interesting targets. And we do spend some money on due diligence in processes here. But there is nothing I can call out or talk about regarding any results from here. But it is a normal part of what we do. A little bit heightened level in the third quarter. And I think that's all.

Ludwig Germann
18:11 - 18:12

Thanks for taking my questions.

Mattias Perjos
18:13 - 18:14

Thank you.

Operator
18:18 - 18:22

The next question comes from Eric Cassel from Danske Bank. Please go ahead.

Eric Cassel
18:24 - 18:40

Hello. Good morning, everyone. First question on the margins. You have said that quality costs were going to taper off a bit now during H2. Have you already seen that help the margin now in Q3 or is it more to come in Q4?

Agneta Palmér
18:42 - 19:18

I think just to say that we are progressing on that trajectory that we have described before when it comes to quality costs, but they still remain elevated compared to normal levels. And that will remain for some time. But that message is the same as before. And just to reiterate, the drivers of the margin act as a continuation of what we have talked about before. So it is pricing, a positive mix shift, and underlying productivity factors. And then in this quarter, a little bit of help from currency.

Eric Cassel
19:20 - 19:24

Okay. But you cannot specify if the effect will be greater in Q4 than it was now.

Agneta Palmér
19:25 - 19:28

I would not count on it being bigger in Q4 than now.

Eric Cassel
19:30 - 19:47

Okay. And then you said in the last conference call that the ventilator comps were going to be a lot cleaner now in H2, but it looks like ventilator demand continues to fall. Do you think that's anything on timing or is the market still perhaps a bit weaker than what you expect?

Mattias Perjos
19:49 - 20:08

Nothing particular to call out. I think it is a market that is normalizing in the wake of a number of players leaving the space here. We have had an uptick in the past, but there is nothing specific to call out here other than sometimes there is a bit of lumpiness when it comes to contracts on ventilators.

Eric Cassel
20:11 - 20:31

Okay. Thank you. And then it looked like balloon pump consumables did fairly well as well. Is that some sort of effect from supply constraints being released in Europe or is there any other factor? And also, if the supply constraint is being lifted, do you have any sort of backlog that you are now bringing into Q4, which you expect to catch up on?

Mattias Perjos
20:33 - 21:17

I think the consumables supply is something we don't really have any restrictions on. That has been fairly smooth for some time. The capacity restrictions are on the balloon pumps themselves, where you know very well the history here. We still have constraints when it comes to everything from certain components to manpower to build the pumps. So, yeah, that is the situation. And we do expect this to be a challenging situation for the remainder of this year as well. I cannot call out a specific dynamic now for Q3 compared to Q4, but until we have worked through the entire supply chain situation regarding capacity, I think we will have a bit of sluggishness when it comes to the hardware.

Eric Cassel
21:19 - 21:33

Okay. Thank you. And then just a quick last one. I did not see a mention of filing in the US. Do you have any update on if you are still aiming for the previous communication on the filing timeline?

Mattias Perjos
21:34 - 21:47

And there is no news to report. We will communicate once it has been submitted. We continue to have a constructive dialogue in these pre-submission meetings with the FDA. So, there is nothing new to share here.

Eric Cassel
21:48 - 21:50

Okay, great. Thank you so much.

Mattias Perjos
21:51 - 21:51

Thank you.

Operator
21:55 - 21:59

The next question comes from Mattias from SEB. Please go ahead.

Mattias
22:01 - 22:19

Hi. Good morning. Thanks for taking my questions. The first one is on Life Science. No comment on sterile transfer on the other side this time around. So I just want to see if this area is still showing solid performance and if momentum is holding up there.

Mattias Perjos
22:21 - 22:46

Yeah. I think generally yes, the momentum is a category where we expect to have good long-term momentum. Then as you know, some of these orders are because of large contracts as well. So you can have some lumpiness quarter by quarter. So in the quarter, the order intake wasn't spectacular here. But we believe that we have confidence going forward in both order intake and sales of sterile transfer products.

Mattias
22:49 - 23:16

That's clear. Thanks. And then just to take a step back, maybe you've singled out these consumables as a contributor to organic order intake in Acute, I think, all throughout last year. So, could you provide some broader context regarding the reason for this strength? And with the new products, I assume that strength will continue into next year.

Mattias Perjos
23:16 - 24:02

Yes, I see. Yeah. That is the assumption; as we have said on many occasions, we believe that this is really a core area for us for the future. We have a very strong market position. So we do benefit from the day-to-day usage of ECMO therapy. In addition to this, we have the launch of Cardiohelp II in CE markets and Hong Kong. So this will be a gradual addition to that part of the business, but I want to underline that the launch takes a while to really roll out properly and see the effect of this in terms of consumable usage as well. But it is a very good start for the next generation of ECMO therapy.

Mattias
24:04 - 24:23

Thanks. I will squeeze in one last question. So you are seeing a lot of mix as opposed to price effect in Q3 year-on-year. I just wanted to see if this is more around the rotation to more margin-accretive revenue streams or if there is anything in particular for Q3 that you want to single out. That's my last one. Thank you very much.

Agneta Palmér
24:26 - 24:43

Thank you. This is the overall trend that we have described now in the ambition to also have this mix shift towards high-margin disposables, which is a little bit more pronounced in Q3 compared to the general trend.

Mattias
24:45 - 24:46

Thank you very much.

Operator
24:51 - 24:55

The next question comes from Thyra Li from UBS. Please go ahead.

Thyra Li
24:57 - 25:10

Good morning. Could you clarify? And for Thyra. Just one question, please. And that was on the Acute Care margin strength. Could you elaborate on how you expect margins in this business to evolve from here and into 2027? Please. Thank you.

Mattias Perjos
25:12 - 25:32

No, it is the short answer. I think we have seen some strength based on the factors we mentioned when it comes to mix, pricing, and some of the underlying improvement work. But we do not comment on either Q4 or the outlook for 2027 when it comes to specific EBITA margins.

Thyra Li
25:33 - 25:34

Okay. Thank you.

Mattias Perjos
25:35 - 25:36

All right. Thanks.

Operator
25:40 - 25:45

The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Sten Gustafsson
25:47 - 26:12

Yes. Good morning. Two questions, if I may. I know you commented on the ECMO. ECMO US filing. Can you give us an update on the CardioSave US filing as well? That would be my first question. And then I have a follow-up.

Mattias Perjos
26:15 - 26:40

Yeah. I think there is not that much to say. We have submitted the applications. We have a dialogue now with the FDA about some follow-up questions on this, but nothing out of the ordinary. We still expect the long approval time. We said 6 to 9 months because it is a very complex product, a complex 510(k) submission. But nothing really to update since last time we reported.

Sten Gustafsson
26:41 - 27:18

That is good. But you have an ongoing dialogue with them, as is usual. Perfect. Thank you very much. My second question is on the Cardiohelp II platform. Well, it is the same product as Cardiohelp II and Cardio. Save up. And what you see here in Europe is where you actually use those products. I noticed that one of your competitors has had some issues, or perhaps not issues, but there was a clinical paper questioning one of their products. Do you see any benefit from that regarding your products?

Mattias Perjos
27:20 - 27:45

No, I think we follow the same news that you do, but I cannot really call out any specific benefits from this adverse news for competitors. I think we remain close to our customers. It is a therapy field where you operate. Depending on the complexity of the patient's situation, you have different choices to make. I think maybe there's some net benefit from this, but nothing that we have seen that we can call out or measure.

Sten Gustafsson
27:47 - 27:51

Okay. Well, thank you. I will get back to the queue.

Unknown 1
27:51 - 27:52

All right. Thank you.

Operator
27:57 - 28:02

The next question comes from David Adlington from JP Morgan. Please go ahead.

David Adlington
28:04 - 28:21

A couple of questions from me, please. Firstly, I was wondering if you were able to quantify any stocking impacts from the Cardiohelp II launch in the quarter. And then secondly, I am just wondering how you are thinking about inflation in 2027. Is there anything you would highlight in terms of particular headwinds? Thanks.

Unknown 1
28:22 - 28:23

Yeah.

Mattias Perjos
28:23 - 28:48

I think there is no stocking impact when it comes to Cardiohelp II in the quarter. Absolutely not. And when it comes to inflation, we do see, of course, an upward pressure when it comes to everything from labor to energy to certain materials, freight and so on. But I think our team has done a great job as well, mitigating this for the most part. Nothing of material impact that we see right now.

David Adlington
28:52 - 28:52

Thank you.

Unknown 1
28:54 - 28:55

Great. Thank you.

Operator
28:59 - 29:14

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Christopher Lilleberg from DNB Carnegie. Please go ahead.

Christopher Lilleberg
29:16 - 29:31

Thank you and good morning. Three questions first, coming back to the visibility here for Q4 sales, I think you need at least 4% to reach the lower end of the guidance. What would you highlight as the main risk of not reaching that?

Mattias Perjos
29:33 - 30:20

I would highlight if there is a slowdown in some of the areas that are kind of book-and-turn in Q4. When it comes to consumables and sterile transfer, those are categories that we depend on. I think that would be one thing that could potentially have an impact. The other factor I would highlight is what we have seen in previous years, where customers are sometimes not entirely ready to receive a shipment of capital goods, most often because something on their part is not finished yet. And then it ends up in the first quarter instead. So that would be the second thing. That is a risk factor here, but nothing else. Nothing out of the ordinary. It's the same dynamics as every year in Q4.

Christopher Lilleberg
30:22 - 30:45

Okay, great. Then I was wondering a little bit about the service margin. I guess high-margin products are making up a larger part of sales there. Given what you have said, why is it not? Why is that not resulting in a better margin? Is it just the leverage effect you have on lower manufacturing of bigger capital equipment, or something else?

Agneta Palmér
30:47 - 31:05

Yes, that is essentially it. You describe it well, as you can see, the gross margin is up somewhat. So we do compensate for it. But overall through the P&L, this leverage effect on the lower levels in the risk category is difficult to fully compensate.

Christopher Lilleberg
31:06 - 31:21

Great. And then the final question; I know it has been asked before, but based on what you say, it seems lower quality costs haven't been a big impact at all on the margin in the third quarter, year over year. Is that correct?

Agneta Palmér
31:22 - 31:30

Yes. That's right. We are seeing that we are continuing to improve in this area, but it is not a material impact that I would factor in in Q3.

Christopher Lilleberg
31:30 - 31:38

So this means for 2027, this should be a pretty big positive tailwind for you.

Agneta Palmér
31:42 - 31:49

Well, overall, we are following this trajectory that we have described before, a gradual step down in quality-related costs.

Christopher Lilleberg
31:52 - 32:03

Okay. But is it possible to say whether the decline is going to be, in absolute terms, lower in 2027 or 2028 versus current levels?

Mattias Perjos
32:05 - 32:13

Yes, it is definitely larger in 2027 compared to 2026 and then larger again in 2028. That is the dynamic we expect.

Christopher Lilleberg
32:13 - 32:14

Okay. Thank you.

Operator
32:19 - 32:26

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Mattias Perjos
32:27 - 32:39

All right. Thank you very much. Thank you for joining us today. I think we already summarized this, and I appreciate the attendance today and the dialogue when it comes to the Q&A, so thanks very much, everyone. Have a great rest of the day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…